Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 1,501 shares, a decline of 78.8% from the June 30th total of 7,095 shares. Based on an average daily volume of 118,747 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.3% of the shares of the company are short sold.

Sigyn Therapeutics Stock Performance

Shares of OTCMKTS SIGY opened at $0.03 on Friday. The company has a 50 day simple moving average of $0.04 and a two-hundred day simple moving average of $0.23. The stock has a market cap of $75,946.00, a price-to-earnings ratio of -0.01 and a beta of -0.08. Sigyn Therapeutics has a 12 month low of $0.01 and a 12 month high of $5.00.

Sigyn Therapeutics (OTCMKTS:SIGY) last announced its quarterly earnings results on Thursday, July 16th. The company reported ($0.42) earnings per share for the quarter.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.